Representing a comprehensive approach to world class mesothelioma treatment and innovative research, the Temple Fox-Chase Cancer Center Mesothelioma and Pleural Disease Program is dedicated to the delivery of high quality care for mesothelioma patients. The facility is pursuing innovative research and multiple projects geared towards offering patients improved outcomes and survival.
Consistently ranked in the top two “Best Hospitals for Cancer” every year since U.S. News & World Report began rating hospitals, Memorial Sloan Kettering is a world leader in patient care, research, and educational programs. In keeping with its singular mission of “ending cancer for life,” the hospital has taken a leading role in the treatment of malignant pleural and peritoneal mesothelioma. Its specialists across multiple disciplines work together to develop and demonstrate new approaches to accurate diagnosis and staging, and compassionate, effective treatment of patients with this rare disease.
The Sidney Kimmel Comprehensive Cancer Center is an NCI-recognized comprehensive cancer center and one of the top cancer treatment centers in the country. Part of Johns Hopkins University, the hospital offers a multidisciplinary team approach and treatment options including surgical oncology, chemotherapy, targeted therapy, and immunotherapy. Peritoneal mesothelioma patients treated here can benefit from the Peritoneal Surface Malignancy Program, while those diagnosed with pleural mesothelioma benefit from the Lung Cancer Program.
The Abramson Cancer Center at Penn Medicine in Philadelphia is considered a world leader in patient care and cancer research. Dedicated to offering cancer patients the newest and most innovative therapeutic advances, the center’s focus on “World-Class Cancer Care Here and Now” reflects its goal of improving the detection, diagnosis, and treatment of cancer. Among the innovative specialty areas is the unique Mesothelioma and Pleural Program that offers comprehensive and compassionate care for those suffering from mesothelioma and pleural disease.
Malignant mesothelioma, a rare form of cancer caused by exposure to asbestos, is an extremely challenging and aggressive illness that is always considered fatal. Even confirming a diagnosis can be difficult, but a recent study conducted by German researchers has concluded that a lung fluid test that measures hyaluronic acid levels is extremely accurate at
Malignant mesothelioma has proven resistant to every cancer treatment. Physicians using varying combinations of chemotherapy, radiation, surgery, and immunotherapy have been able to extend survival for some patients, but have not yet found a way to stop the aggressive cancer from claiming the lives of its victims. Now researchers at the Roswell Park Cancer Center
When a person is diagnosed with malignant mesothelioma or any other asbestos-related cancer, they immediately focus on where their illness came from. Those who decide to pursue justice file suit against manufacturers and others who negligently exposed them to the carcinogen, and those companies generally take steps to defend themselves or to minimize their liability.
The statute of limitations in mesothelioma lawsuits and other similar personal injury cases is three years from when the victim knows or should have known of their illness. Though this may seem clear cut, asbestos companies often try to use this limitation to their advantage to have cases dismissed. A recent attempt to have a
Traditionally, exploring the roots of malignant mesothelioma involves examining how the body’s cells respond when exposed to asbestos. But a group of researchers from the University of Pennsylvania has taken a different approach, exploring how asbestos particles change once introduced into the body. This unique perspective may lead to new approaches to treatment.
As is true with so many other types of cancers, the first line of treatment for malignant mesothelioma is chemotherapy. Despite its many side effects, most mesothelioma patients receive chemotherapy as part of a multi-modality protocol that adds on surgery and/or radiation therapy. But as newer drugs are developed that approach cancer cells in different